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Case presentation
A 61-year-old white woman was referred to the University Hospital
for management of rapidly progressive glomerulonephritis and pulmo-
nary hemorrhage. One week prior to admission, she developed a cough
productive of a small amount of bloody sputum; the cough and
hemoptysis became worse over the succeeding week. Chest x-ray
showed bilateral pulmonary infiltrates in a "butterfly" pattern. She was
admitted to another hospital, where she was found to be hypoxic.
Arterial blood gas analysis (with the patient breathing room air) showed
pH, 7.42; PCO2, 36 mm Hg; and P02, 58 mm Hg. At this time she was
coughing up about one-quarter cup of bright red blood per hour.
Urinalysis showed 3 + proteinuria, microscopic hematuria, and many
granular and red blood cell casts/high-power field. The BUN and serum
creatinine were 38 and 2.5 mgldl respectively. Three months earlier (at
the time of an elective cholecystectomy) the BUN had been 20 mg/dl;
serum creatinine, 1.5 mg/dl; and hematocrit, 31%. The patient was
treated with erythromycin, oxygen, and blood transfusion, and was
transferred to the University Hospital with the provisional diagnosis of
Goodpasture 's syndrome.
Careful questioning disclosed that the patient had experienced frontal
headaches and nasal congestion for approximately one year. On one
occasion, she had been treated with topical antibiotics for pain and
"conjunctivitis" of the left eye. She also had experienced intermittent
arthralgia and stiffness of the elbows, wrists, and knees for several
months. She had not experienced fever, chest pain, rash, hair loss, oral
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ulceration, hearing loss, or nasal discharge. Also she had no recent
history of "flu-like" symptoms or exposure to noxious fumes. The
patient did not smoke tobacco.
Physical examination revealed a well-developed, healthy looking,
white female. She was in no acute distress but frequently coughed small
amounts of bright red blood during the interview. She was afebrile,
slightly pale, moderately tachypneie, and the heart rate was 100
beats/mm. The blood pressure was 130/70 mm Hg without abnormal
postural change. The ears, nose, and throat were normal, and no sinus
tenderness was present. No lymphadenopathy was apparent, and the
joints and skin were normal. Cardiac examination was normal and the
lungs were clear to percussion and auscultation. Apart from two
well-healed surgical scars, abdominal examination was unremarkable.
No edema was present. The urine contained 2 + protein; microscopic
examination revealed numerous erythrocytes and many red cell casts
and granular casts. The serum creatinine had increased to 3.9 mg/dl;
urine output exceeded I liter/day. Chest x-ray confirmed the presence
of bilateral alveolar-interstitial infiltrates more marked on the left (Fig.
I).
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A percutaneous renal biopsy was performed on the morning of
admission. Later that day, a regimen of oral cyclophosphamide, 2
mg/kg, and prednisone, 1 mg/kg, was started when it became known
that immunofluorescent examination of the renal biopsy specimen was
negative for glomerular immunoglobulins and was positive only for
fibrinogen in a crescentic distribution in some glomeruli (Fig. 2A). An
open lung biopsy was provisionally scheduled for the second day after
transfer, but by that time the cough had improved, the hemoptysis had
resolved completely, and the patient felt considerably more comfort-
able. Lung biopsy therefore was deferred. The final renal biopsy report
was as follows. Light microscopy showed a focal and segmental
necrotizing glomerulonephritis with cellular crescents in 50% of glomer-
uli (Fig. 2B). A prominent periglomerular inflammatory infiltrate was
present together with interstitial edema. No evidence of intrarenal
vasculitis was found. The immunofluorescent findings were as de-
scribed in the preliminary report. Electron microscopic examination
showed glomerular capillary collapse, with fibrin and mononuclear cells
in Bowman's space (Fig. 2C). Electron-dense deposits were not seen.
The features of crescentic and necrotizing glomerulonephritis without
immune deposits were thought to be consistent with idiopathic, rapidly
progressive glomerulonephritis or a vasculitic syndrome.
The serum creatinine level rose over 6 days to a peak of 5.4 mg/dl
while the pulmonary infiltrate improved. Urine output remained nor-
mal, and the serum creatinine level eventually began to decline. Urine
protein excretion was 470 mg/24 hr. Discharge was delayed because of
progressive neutropenia (2400/mm3) and anemia. The patient was
discharged after 3 weeks with microscopic hematuria, a serum creati-
nine of 3.5 mg/dl, a white blood cell count of 5600/mm3, and a clear
chest x-ray (Fig. 1). The following laboratory investigations were either
negative or normal: antinuclear antibody, radioimmunoassay for
antiglomerular basement membrane antibody, serum complement, hep-
atitis Bs, cryoglobulins, and peripheral eosinophil count, The patient's
serum contained IgG antibodies that stained the cytoplasm of normal
human leukocytes to a dilution of 1:20 (control <1:10).
We have followed this patient for almost 2 years since her acute
illness. Two months after onset of the illness, prednisone was switched
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Fig. 1. Chestx-ray before (A)and two weeks after (B) treatment was started with cyclophosphamide and prednisone. Note the alveolar-interstitial
infiltrate in the left upper zone and right mid zone in A, which has completely resolved in B.
to an alternate-day regimen and was then discontinued over the course
of 4 months. The dose of cyclophosphamide at discharge was 100 mg
daily, but was reduced within 4 months to 50—75 mg daily because of
neutropenia. Serum creatinine declined progressively and stabilized at
2.2 mg/dl after approximately 10 months. Microscopic hematuria also
resolved after about 10 months. Urine protein excretion remains at
400—700 mg/24 hours. The long-term course was complicated by a bout
of herpes zoster and an episode of diverticulitis with bacteremia. The
latter resolved without further complications after a short course of
intravenous antibiotics. Cyclophosphamide was continued for IS
months after complete resolution of all symptoms. The dose was then
tapered and finally discontinued after a total duration of 20 months. At
last followup, the serum creatinine was 2.0 mg/dl, blood pressure was
normal, and the urine sediment showed only occasional red blood cells.
Discussion
DR. DAVID J. SALANT (Associate Professor of Medicine,
Evans Department of Clinical Research at University Hospital,
Boston University Medical Center, Boston, Massachusetts):
Each new case of rapidly progressive glomerulonephritis
(RPGN) presents the clinician with a diagnostic and therapeutic
challenge. This patient's presentation—rapidly declining renal
function, hematuria with red blood cell casts, and mild protein-
uria—was entirely compatible with a diagnosis of RPGN. In
managing such a patient one must specifically diagnose the
underlying illness and initiate therapy without delay for two
important reasons. First, the type of treatment selected de-
pends on the diagnosis of the primary disease, because no one
form of therapy is effective for all causes of RPGN [1]. Second,
unless appropriate therapy is instituted promptly, the prognosis
of RPGN is poor. Patients who receive ineffective or no
treatment have a 2-year renal survival rate of less than 30% [2],
To diagnose a specific disease from the broad differential
diagnosis of this syndrome (Table 1), one generally relies on a
combination of features that include the clinical renal manifes-
tations, extrarenal symptoms and signs, serologic abnormali-
ties, and renal immunopathology. Clinical renal manifestations
are relatively "soft" criteria on which to base a diagnosis but,
in the patient under consideration, the absence of nephrotic-
range proteinuria and hypertension tended to favor anti-glomer-
ular basement membrane (anti-GBM) nephritis, idiopathic
RPGN without immune deposits, or vasculitic syndromes such
as microscopic polyarteritis nodosa (PAN) or Wegener's gran-
ulomatosis (WG) rather than the immune-complex glomerulo-
nephritides shown in Table 1.
Extrarenal manifestations of a systemic disease are important
clues to the diagnosis in RPGN, especially when they display a
typical spectrum of abnormalities as in systemic lupus erythem-
atosus (SLE), Henoch-Schönlein purpura (HSP), and essential
mixed cryoglobulinemia (EMC) [1], or characteristic features
such as the upper respiratory tract destruction that can occur
with WG. Pulmonary hemorrhage, as in this patient, can be of
considerable diagnostic help in narrowing the differential diag-
nosis to one of the specific pulmonary-renal syndromes listed in
Table 2. Several nonspecific pulmonary manifestations can
occur with similar or greater frequency in any patient with
RPGN, however, and these should be excluded first. Any
patient with oliguric acute renal failure is at risk of volume
overload and pulmonary edema. Pulmonary infection may be
incidental or causally related to a proliferative glomerulonephri-
tis [1], and minor hemoptysis or transient pulmonary infiltrates
are seen in about 30% of cases early in the course of "deposit-
free" idiopathic RPGN [3]. Right-sided infective endocarditis is
an important cause of multilobar septic pulmonary emboli and
can cause RPGN [1, 4]. After excluding these nonspecific
disorders in the patient described, we had to determine whether
she had anti-GBM disease (Goodpasture's syndrome), SLE, or
vasculitis (particularly WG, as there were no atopic features to
suggest allergic granulomatosis). On purely clinical grounds we
might have excluded Goodpasture's syndrome because it oc-
curs more often in young men, and because of the patient's
history of sinusitis and arthralgia. But these features are merely
demographic or too subjective to be firm diagnostic criteria.
Serologic studies could have been of considerable diagnostic
B
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Table 1. Immunopathologic classification of crescentic and/or
necrotizing glomerulonephritis
Linear immune deposits (anti-GBM nephritis)
Goodpasture' s syndrome
Nephritis without pulmonary hemorrhage
Granular immune deposits (immune-complex nephritis)
Systemic diseases
Systemic lupus erythematosus
Henoch-Schönlein purpura
Postinfectious
Essential mixed cryoglobulinemia
Primary glomerular diseases
Membranoproliferative glomerulonephritis
IgA nephropathy
Idiopathic immune-complex RPGN
No immune deposits
Idiopathic RPGN
Systemic vasculitis
Wegener' s granulomatosis
Polyarteritis nodosa
Table 2. Major causes of lung purpura in association with RPGN
Pulmonary-renal syndromes Nonspecific
Goodpasture 's syndrome Pulmonary edema
Wegener' s granulomatosis Infection
Allergic granulomatosis Pulmonary embolism
Systemic lupus erythematosus
Fig. 2. Renal biopsy findings. A Immunofluorescent micrograph show-
ing staining for fibrin/fibrinogen-related antigens. B Light micrograph of
a crescentic glomerulus. Note compression and distortion of the gb-
merular tuft (large arrows) by a large, pleiomorphic cellular crescent
(arrow heads); perigbomerular infiltrate of mononuclear cells; and
disruption of Bowman's capsule (small arrows). C Electron micrograph
of a glomerular capillary showing mononuclear cells in the capillary
lumen (small arrowhead) and urinary space (large arrowhead). No
electron-dense deposits were visible on higher magnification of this or
several other fields. Ep, visceral epithelial cell.
value if they had been available immediately. The presence of
antinuclear and anti-dsDNA antibodies and hypocomple-
mentemia in severe lupus nephritis, anti-GBM antibodies in
Goodpasture's syndrome, and the absence of these specific
findings in WG would have readily distinguished among the
major differential diagnoses in this patient. Indirect im-
munofluorescent studies for anti—GBM antibody can be per-
formed in a matter of hours and have good specificity for
anti-GBM nephritis, albeit less sensitivity than a good radioim-
munoassay [2, 5, 6]. Unfortunately, these studies are not
available to most clinicians as emergency procedures.
In the patient we are discussing, the three most likely
diagnoses and their treatments were: plasma exchange for
Goodpasture's syndrome [61, high-dose steroids, possibly with
immunosuppressive agents, for SLE [71, and cyclophospha-
mide with low-dose steroids for WG [81. Considering that
serologic confirmation of the diagnosis was not immediately
available, that therapy should be instituted immediately, and
that the appropriate form of therapy is different for each of the
diagnoses [91, the most expeditious diagnostic procedure was a
renal biopsy. This served three major purposes. First, the
immunofluorescent findings were obtained within hours, en-
abling us to classify the patient's illness into one of the three
categories shown in Table 1. The absence of linear or granular
immunoglobulin deposits in this patient unequivocally excluded
Goodpasture's syndrome and SLE (or any other form of
immune-complex glomerulonephritis). Second, light micros-
copy confirmed the diagnosis of crescentic glomerulonephritis.
Third, light microscopy showed the crescents to be mainly
cellular without extensive scarring of glomeruli and with good
preservation of tubulointerstitial architecture. Although a defi-
nite diagnosis of WG, or most other forms of vasculitis, cannot
be made on the basis of a renal biopsy, the immunopathologic
findings and extrarenal manifestations in this patient were
sufficient to suggest that disease, and we instituted cyclophos-
phamide therapy. The patient's excellent response to treatment
and gratifying "medium-term" outcome further suggest that
she had Wegener's nephritis and pulmonary disease.
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Open lung biopsy is the most reliable means of establishing
the diagnosis of WG and distinguishing it from deposit-free,
idiopathic, crescentic glomerulonephritis associated with non-
specific lung disease. Several independent observers have
found that the serum of patients with active WG and closely
related vasculitic syndromes contains IgG antibodies that react
with granulocyte cytoplasmic antigens [10—12]. Antibody titers
correlate with disease activity, and binding is independent of Fc
[11]. The test is quickly and easily done and if, as the first three
published reports suggest, it is specific for active WG and
negative for SLE, it will be of considerable diagnostic value.
The nature of the cytoplasmic antigens has not been deter-
mined; nor has it been established whether this reactivity is the
same as that described with Ro (SS-A), a cytoplasmic nucleo-
protein identified by certain lupus sera and sera of some
patients with active WG [13]. It is noteworthy that the serum of
the patient under discussion contained anticytoplasmic antibod-
ies.
The predominantly cellular nature of the crescents in this
patient's biopsy (Fig. 2) and her relatively well-preserved renal
function at the onset of treatment probably contributed to her
favorable response. Fibrous scarring of crescentic glomeruli
can develop rapidly [14], as recently illustrated in rat [15] and
rabbit [16] models of crescentic glomerulonephritis induced by
accelerating the autologous phase of anti-GBM nephritis. These
experiments showed that crescents evolve from a fibrin cast in
Bowman's space, through a predominantly cellular phase, to an
organized fibrocellular scar containing cross-linked interstitial
collagens, in as brief a period as 3 to 4 weeks [15—17]. The level
of renal dysfunction and likelihood of reversal with treatment
therefore reflect not only the extent of glomerular involvement
but also the point along this continuum at which therapy is
started. Inflammatory cell infiltration and endogenous paren-
chymal cell proliferation are potentially reversible events but
fibrosis is not. Cellular crescents sometimes resolve, leaving
small fibrotic scars, which allows improvement in the inflam-
matory and hemodynamic alterations [1] affecting renal func-
tion. Large fibrous crescents that compress and collapse the
glomerular tuft are unlikely to resolve; these generally lead to
glomerular obsolescence, tubular atrophy, and permanent renal
dysfunction. This difference probably explains why, in patients
with RPGN—especially those with anti-GBM nephritis—the
probability of recovery, or at least stabilization, is highest in
those with relatively well-preserved renal function (6, 18—20).
For example, Savage and colleagues noted that patients with
anti-GBM nephritis whose serum creatinine exceeded 600
mol/liter (6.5 mgldl) did not respond to plasmapheresis 16]. In
contrast, the prognosis was good in nonoliguric patients whose
serum creatinine was below 600 mol/liter (6.5 mg/dl) when
treatment was started [6]. The same is generally true for other
forms of RPGN [18], although even dialysis-dependent patients
with lupus nephritis, WG, postinfectious glomerulonephritis,
and idiopathic RPGN have been known to recover some renal
function with appropriate treatment [2, 19]. Long-term renal
survival in such patients with these other forms of RPGN tends
to be worse than in those whose renal function is well preserved
when treatment is begun, however [18—22].
This patient's renal biopsy (Fig. 2) also illustrates certain
points of pathogenetic importance, which I will discuss later.
The crescents appeared to be composed of a pleiomorphic
collection of cells together with a hyaline stroma that stained
positively on immunofluorescent examination with antiserum to
fibrin-related antigens. Staining for fibrin also was evident
within the glomerular tuft. In some areas, a striking periglomer-
ular infiltrate of mononuclear cells appeared to merge with the
crescent through breaks in Bowman's capsule. This is a well-
recognized finding in both clinical [14, 18, 23, 24] and experi-
mental [15, 25] proliferative glomerulonephritis, but only re-
cently have investigators begun to examine the role these
mononuclear cells, which are derived from interstitial vessels,
might play in the development of periglomerular fibrosis [26],
disruption of Bowman's capsule [15], and perhaps even cres-
cent formation.
Several reviews have dealt extensively with therapy of idio-
pathic RPGN [2], vasculitis [27], and lupus nephritis [8]. Except
for a controlled, prospective, collaborative study of severe
lupus nephritis, which showed no beneficial effect of plasma
exchange on multiple outcome variables [28], no major thera-
peutic advances have occurred since publication of those
articles. I therefore shall not reiterate their contents here and
will defer discussing the management of RPGN. Instead, the
rest of this discussion will emphasize recent discoveries that
enhance our understanding of the clinical and pathologic man-
ifestations of RPGN. I shall focus on the immunopathogenesis
of crescentic glomerulonephritis because it is only by under-
standing the fundamental pathobiology of the glomerular lesion
that we will be able to proceed from empiric to rational
treatment.
Lung purpura with RPGN
Goodpasture's syndrome. Pulmonary hemorrhage occurs in
approximately two-thirds of patients with anti-GBM nephritis
(Goodpasture's syndrome) [29—3 1] and is due to deposition of
anti-basement membrane (BM) antibodies on the alveolar BM
[32]. The remaining one-third of patients without symptomatic
lung disease might have lung deposits of weakly pathogenic
antibody [31] but, on the basis of experimental data [33, 34], it
appears more likely that anti-BM antibodies fail to bind to the
alveolar BM in such cases. Although antibodies from patients
with Goodpasture's syndrome (GP) and those from patients
with non-GP anti-GBM nephritis can differ in their ability to
bind extraglomerular BMs [33], recent experimental observa-
tions suggest that alveolar capillary anatomy and the chemistry
of the GP antigen are also important factors.
In contrast to the highly fenestrated glomerular endothelium,
alveolar (and most other) capillary endothelia do not have open
fenestrae and provide a very effective barrier to the passage of
anti-BM antibodies. If this barrier is disrupted, antibodies can
gain access to antigens in the alveolar BM and cause injury.
Jennings and coworkers injected rats with anti-alveolar BM
antiserum and exposed some of the animals to toxic concentra-
tions of inhaled oxygen. All rats developed GBM deposits of
antibody as well as nephritis, but only those exposed to 100%
oxygen developed alveolar BM deposits of antibody and fatal
pulmonary injury [34]. A similar outcome was not observed in
rats exposed to hydrocarbon vapors and anti-GBM antibody
[35]; additional factors therefore might be important for alveolar
BM binding.
Advances in basement membrane biochemistry have led to
the identification, isolation, and characterization of the GP
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antigen [36—38]. Further, this work has revealed features that
might help explain why extraglomerular capillaries are less
susceptible than are glomeruli to injury by circulating anti-BM
antibodies. For several years it has been known that antisera
from patients with anti-GBM nephritis bind to collagenase-
resistant components of the GBM [5, 39]. In fact, successful
immunoassays for anti-GBM antibodies, which employ colla-
genase-solubilized GBM as substrate [5, 6, 401, have depended
on this property. Type IV (basement membrane) collagen is a
heterotrimer composed of two al(IV) and one a2(IV) chains
arranged in a triple helix interrupted by two non-collagenous
(NC1 and NC2) regions [41] (Fig. 3). Type IV collagen differs
from interstitial collagens in that it is laid down as a three-di-
mensional lattice of procollagen molecules containing both
collagenous and noncollagenous domains; this arrangement
imparts strength and flexibility to the BM. The supramolecular
organization is still uncertain, but it is known that four adjoining
molecules of type IV collagen are associated via their amino
terminals (7S domain), and that each molecule is also linked
through its carboxyterminal NC1 (globular) domain to another
type IV collagen molecule [41] (Fig. 3). Lateral associations
between adjacent collagen chains, or through the junctions
described above, complete the three-dimensional structure.
Using gel fractionation of collagenase digests of human GBM,
Wieslander and colleagues showed that antisera from patients
with anti-GBM nephritis (GP antisera) react exclusively with a
26 kD noncollagenous monomeric peptide (and 48 kD dimeric
aggregates thereof) [37]. Antisera from patients with OP also
reacted with a similar collagenase-resistant molecule from
bovine GBM and bovine type IV collagen [42]. This molecule
from bovine GBM proved to be one (M2) of the three
noncollagenous monomeric peptides (Ml, M2, M3) in the
globular domain at the carboxyterminal end of type IV collagen,
each representing the NC1 of the two al(IV) chains and one
a2(IV) chain [38, 43—45] (Fig. 3). Sera from patients with a
variety of immunologic renal diseases (such as SLE, IgA
nephropathy, PAN) react with other extracts of GBM [46], but
only patients with anti-GBM nephritis have antibodies reactive
with collagenase digests of GBM [46] and the —28 kD M2
monomer or 42—50 kD D2 dimers contained within NC1 [38, 43].
Whereas GP antisera and glomerular eluates are unquestionably
nephritogenic [47], the GBM reactivity in the other diseases is
of doubtful significance.
The location of the OP antigen in type IV collagen also might
explain why only some patients with circulating anti-GBM get
pulmonary disease. Despite the ubiquitous distribution of type
IV collagen (and hence the GP antigen) in all BMs, specific
anti-GP antisera do not readily bind to extraglomerular BMs
even when the endothelial barrier is abrogated by sectioning of
the tissue [48]. Yet if the molecule is dissociated by treatment
with 6 M guanidine [44] or with acid-urea [48], increased
binding can be demonstrated, probably because the OP epitope
is normally enfolded within the tertiary structure of the
hexanieric NC! complex formed by adjacent type IV collagen
molecules in tissue [44, 45]. Tissue-damaging agents therefore
might facilitate the binding of anti-OBM antibodies to GP
antigen within the alveolar BM, either by damaging the alveolar
capillary endothelium or by exposing GP epitopes hidden within
the globular domain of type IV collagen (Fig. 4). This hypoth-
esis might explain the increased frequency of pulmonary hem-
Fig. 3. Schematic representation of the lattice-like assembly of several
type IV collagen molecules. Each molecule comprises a triple helix and
two noncollagenous regions, shown as the clear oval (NC2) and circular
(NCI) areas. Four molecules associate via amino-terminal segments to
form the 7S region. Two adjacent molecules are also joined lengthwise
at the globular domain by bonds formed between their respective NC 1
regions. The enlargement shows details of the globular domain. Mono-
meric noncollagenous peptides (Ml, M2, M3) at the carboxyterminal
end of each collagen chain are linked via dissociable (S-S) and nondis-
sociable convalent bonds to their counterparts on the adjacent molecule
to form dimers. Lateral associations that confer a third dimension to the
structure are not shown. (Adapted from Refs. 41 and 45.)
orrhage in cigarette smokers [49], as well as the sporadic
association between Ooodpasture's syndrome and exposure to
volatile solvents [30, 50] and viral infections [51]. An alternate,
and once popular, notion—that anti-BM antibody production is
triggered by solvent-induced alveolar injury [501—has not been
supported by epidemiologic data [521. Possibly, in some cases,
cryptic OP antigens in nonrenal BMs might be exposed by
injurious agents and lead to autoantibody production. If this
were true, GBM would be expected to bear the brunt of injury
because of the anatomic and biochemical characteristics I have
discussed.
Other causes of lung purpura with RPGN. Hemoptysis,
sometimes massive and life-threatening, also can occur in WG
[9, 21, 53, 54], and SLE [55—57]. In WG, scant evidence
suggests that humoral immunity plays any role in pulmonary
injury, but the presence of necrotizing granulomatous and
vasculitic lesions, accompanied by a prominent infiltrate of T
lymphocytes and macrophages [58], suggests that cell-mediated
immune mechanisms might be important in the pathogenesis.
This belief is supported by the responsiveness of the pulmonary
lesions in WO to cyclophosphamide. Pulmonary involvement in
SLE is less common than is pleutitis and most often is infec-
tious and secondary to immunosuppression [55—57]. However,
'lupus pneumonitis" has been documented [57] and, although
the primary lung pathology is often obscured by secondary
Globular
domain
7S
Triple helix
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Normal Circulating Subclinical lung injury
anti-GBM (tobacco, solvents, viruses)
processes, some evidence indicates that alveolitis, interstitial
edema, and hyaline membranes might result from immune-
complex deposition [561.
In essence, the immunopathogenesis of pulmonary injury in
pulmonary-renal syndromes is similar to that in the kidney, with
evidence for anti-BM, immune-complex, and possibly cell-
mediated mechanisms. The effector systems that mediate tissue
damage in the lung have been studied extensively [59, 60] and
will not be reviewed here. However, insights gained from such
studies have aided our understanding and investigation of
glomerular injury, especially with regard to the role of oxidants
and proteases.
Immunopathogenesis of crescentic glomerulonephritis
Injury to the glomerular capillary wall (GCW) is an important
initiating event in the formation of a glomerular crescent. The
events that follow the injury are similar to those involving
capillary injury and wound healing elsewhere in the body,
except that these occur in Bowman's space instead of in the
perivascular connective tissue. An immunologically mediated
inflammatory insult is responsible for GCW injury in most
forms of crescentic glomerulonephritis, but similar processes
may follow GCW disruption from any cause and probably
account for the occasional crescents seen in other noninflam-
matory glomerular diseases [14].
Humoral immunity. The pathogenetic role of anti-GBM anti-
bodies in human RPGN was unequivocally established 20 years
ago when Lerner and colleagues induced linear GBM deposits
and nephritis in subhuman primates by passively transferring
antibodies eluted from the kidneys of patients with Good-
pasture's syndrome [47]. Studies in animal models induced by
active immunization with GBM (Steblay's nephritis) [61] or
passive infusion of heterologous anti-GBM antisera (Masugi's
or nephrotoxic serum nephritis) also demonstrated the nephri-
togenic role of anti-GBM antibodies [31], and subsequent
studies of anti-GBM nephritis helped to elucidate the mecha-
nisms of GCW injury [31, 62]. Similarly, the injurious effect of
immune complexes has been well established in animal models
[31, 62, 63] and most likely accounts for the proliferative,
exudative, and sometimes crescentic glomerular lesions in
postinfectious GN, lupus nephritis, and the other "immune-
complex" glomerulonephritides shown in Table 1.
None of the established 'humoral" models adequately ex-
plains the pathogenesis of glomerular injury in the 40% or more
of patients with crescentic glomerulonephritis in which deposits
are absent. Morphologic abnormalities, including focal glomer-
Fig. 4. Hypothetical model explaining why
certain patients with circulating anti-GBM
Experimental antibody are predisposed to alveolar injury.
Normal alveolar capillary endothelium is
100% Oxygen relatively impermeable to antibody. The
Goodpasture (GP) antigen resides on
monomeric (M2) and dimeric (D2) peptides in
NC 1 and is normally hidden within the6M uanidine globular domain. Endothelial permeability and
Acid-urea the cryptic nature of the GP antigen can be
altered by experimental conditions that may
have clinical counterparts.
ular tuft necrosis and interruptions in the continuity of the GBM
[3], suggest that GCW injury is also an important precondition
for crescent formation in "deposit-free" crescentic glomerulo-
nephritis, either idiopathic or secondary to vasculitis [64, 651.
Some authors have suggested that cases of "deposit-free"
crescentic glomerulonephritis represent examples of transient
immune-complex nephritis in which the immunoglobulin depos-
its are no longer evident at the time of biopsy [66]. An alternate
view is that cell-mediated immunity might play a role in the
absence of a humoral response.
Cell-mediated immune mechanisms. Although few good
models of deposit-free crescentic glomerulonephritis exist, sev-
eral clues have led investigators to examine the possible role of
cell-mediated immune mechanisms. Mononuclear cells can be
demonstrated in the hypercellular glomerular tufts and cres-
cents of diseased glomeruli, and macrophages can be grown
from such glomeruli obtained from patients and experimental
animals with crescentic glomerulonephritis (Table 3). Lympho-
cytes also have been found in crescentic glomeruli [26, 67], and
lymphocyte reactivity to a range of putative antigens has been
demonstrated in patients with various types of proliferative
glomerulonephritis [68].
Evidence for the participation of T cells in proliferative
glomerulonephritis is derived from studies on the autologous
phase of experimental anti-GBM nephritis. Although the pres-
ence of infiltrating mononuclear cells in glomeruli suggested a
delayed-type hypersensitivity reaction, more direct evidence
was required because macrophages bear receptors for comple-
ment C3b (CR!) and immunoglobulin Fc [69] and can be
recruited to an inflammatory focus via the immune adherent and
chemotactic properties of C3b and C5a [25, 70] and by adhesion
to Fe [7!]. To examine this issue, Bhan and colleagues
"planted" subnephritogenic quantities of rabbit anti-GBM IgG
or immune complexes containing rabbit anti-BSA IgG in the
glomeruli of rats. Endogenous glomerular cell proliferation and
macrophage infiltration occurred only after rats received T cells
passively transferred from donors specifically sensitized to
rabbit IgG [72, 73]. Although these and similar studies [74]
showed the potential ability of sensitized T cells to participate
in glomerular injury, the model systems were designed to
maximize the chances of eliciting a T-cell effect; nonetheless,
glomerular damage was modest and did not resemble the severe
lesions and functional derangements seen in rats with acceler-
ated autologous-phase anti-GBM nephritis [15, 75, 76]. Also
one cannot exclude a synergistic injurious effect of the so-called
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Table 3. Role of the monocyte/macrophage in crescentic
glomerulonephritis (GN)
Observation Disease or model References
Monocytes infiltrate Anti-GBM nephritis 75, 76, 95, 96
glomerular tuft Serum-sickness nephritis
Other experimental GN
Human proliferative GN
98—100
25, 70
93, 94, 159
Macrophages comprise Autologous anti-GBM 154
up to 30% of cells in nephritis
crescents Human crescentic GN 116, 155—157
Macrophages grow from Experimental and human 92, 97
explanted glomeruli in crescentic GN
increased numbers
Macrophage depletion Autologous anti-GBM 75, 101
abrogates proteinuria nephritis
and proliferative ON Acute serum sickness
nephritis
101
Macrophage depletion Autologous anti-GBM 144
inhibits glomerular nephritis
fibrin deposition
"subnephrotoxic" dose of heterologous antibody that served as
the planted antigen.
There is certainly no a priori reason why cell-mediated
immune mechanisms should not play a role in the injury of
glomerular cells or matrix. A potential source of antigen-
presenting, bone marrow-derived, Ia, maci-ophage-like cells
resides in the rat glomerular mesangium [77, 78]; small numbers
of T lymphocytes can be found in the glomeruli of rats with
accelerated autologous anti-GBM nephritis [26, 67, 79]; and
glomeruli from such rats recently have been shown to release
lymphokine-like activity that inhibits the in-vitro migration of
macrophages [79]. Production of this macrophage migration-
inhibition factor (MIF) correlated with the presence of T cells
and macrophages in glomeruli, all of which were abrogated
when T-cell sensitization was prevented by cyclosporine A
pretreatment [79]. These findings provide an important clue that
sensitized T cells in glomeruli might direct the influx of mono-
nuclear phagocytes. These data further correlate with indirect
studies of cell-mediated immune mechanisms in human glomer-
ulonephritis, in which activated lymphocytes were detected by
lymphoblast transformation or MIF production in response to a
variety of putative antigens [68]. Unfortunately, these animal
studies share the same handicap as other experiments that
employ immunosuppressed [80] or T cell-deficient [81] animals
to demonstrate a pathogenetic role for T cells: these conditions
also preclude the development of an antibody response and
therefore fail to distinguish between cellular and humoral
events.
The best available evidence of an antibody-independent role
for T cells in inducing proliferative glomerulonephritis is de-
rived from a study of B cell-deficient chickens immunized with
GBM [82] (Table 4), In this study, Bolton and colleagues
showed that bursectomized chickens developed proliferative
glomerulonephritis (including crescent formation in 24%) in the
absence of glomerular deposits of anti-GBM. The glomerular
lesions in B cell-deficient chicks did not differ from those in
their B cell-replete counterparts, all of whom had linear IgG
deposits on their GBM. Furthermore, [3H]thymidine-labeled
lymphocytes from immunized bursectomized chickens mi-
Circulating Linear GBM Glomerular
anti-GBM deposits histology
Positive
(%) Titer '
Positive
(%)
Intensity
(0—4+)
Size"
(units)
Crescents
(%)
N 100 >2000 100 2.19 19.8 38
Bsx 32 <100 36 0.53 20.8 24
a From Ref. 82; only mean values are shown.
b Average glomerular size in unimmunized chicks: N = 13.6, Bsx =
14.9.
In Bsx the presence of glomerular proliferation and crescents did
not correlate with anti-GBM titers or glomerular deposits.
grated to the glomeruli of normal chickens after passive trans-
fer. The same workers subsequently produced glomerular le-
sions in normal chicks by transferring sensitized lymphocytes
derived from the kidneys or spleens of syngeneic chicks immu-
nized with heterologous or isologous GBM in adjuvant [831.
Although the aforementioned studies provide strong circum-
stantial evidence that cell-mediated immune mechanisms par-
ticipate in deposit-free crescentic glomerulonephritis, an impor-
tant question remains. Given that sensitized T cells can only
"see" antigen if it is presented by accessory cells bearing the
appropriate class-Il histocompatibility phenotype, what cells
presented the relevant endogenous or exogenous antigens in the
studies I have described? Possible candidates might include
resident or infiltrating macrophages or activated endothelial
cells [84].
Inmost cases of crescentic glomerulonephritis, the triggering
stimulus to the immune response, whether humoral, cellular, or
both, is unknown. An exogenous antigen, as in postinfectious
glomerulonephritis, can be implicated in some patients, and a
history of "viral-like" illness is not uncommon in the other
apparently cryptogenic varieties. Such infections might play a
role in initiating an autoimmune humoral or cellular reaction, or
might contribute an exogenous antigen for immune-complex
formation. These questions have been most critically examined
in SLE with respect to autoreactivity against DNA and other
self antigens, and are reviewed in detail elsewhere in another
Nephrology Forum [85].
Mediation of glomerular capillary wa/I injury in
crescen tic glomeru/onephritis
Studies in experimental anti-GBM and immune-complex gb-
merulonephritis have elucidated several mechanisms by which
GCW injury might occur (Fig. 5). These mediation systems
have been discussed in detail elsewhere [62, 63] and include: a
direct effect of antibody; antibody-directed, complement-medi-
ated injury through the action of leukocytes or the membrane-
attack complex (MAC); and antibody-directed, complement-
independent injury mediated by leukocytes. These systems will
be reviewed here only in the context of gbomerular inflammation
and crescent formation.
Role of complement and neutrophils. Complement-mediated
chemotaxis and immune adherence of neutrophils are important
in acute, exudative glomerulonephritis, in which hypercellular-
ity is limited to the glomerular tuft. This hypercellularity is
Table 4. Response of normal (N) or bursectomized (Bsx) chickens to
immunization with bovine GBM
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Fig. 5. Schematic representation of potential
and established humoral and cellular
mediators of glomerular capillary wall injury
and glomerularfibrin deposition in
proliferative/exudative glomerulonephritis.
LPS, bacterial endotoxin; IL-I, interleukin 1;
TNF, tumor necrosis factor; PMN,
polymorphonuclear leukocyte; ROS, reactive
oxygen species.
observed in the heterologous phase of anti-GBM nephritis in
rabbits and rats [31, 62, 63, 861, and in certain forms of acute,
experimental, immune-complex glomerulonephritis [25, 701.
Inflammatory-cell influx and immune adherence are favored
when the immune reaction in the GCW occurs in close prox-
imity to the circulation, as in the subendothelial space [251.
Studies of heterologous anti-GBM nephritis in C6-deficient
rabbits by Groggel et al showed that complement also can
directly injure the GCW through its membranolytic action [871.
This report indicates that the MAC in glomeruli of patients with
anti-GBM [881, lupus [891, and poststreptococcal nephritis [90]
might have a pathogenetic role. Although neutrophils also have
been implicated in autologous anti-GBM nephritis in rabbits (a
model of crescentic glomerulonephritis [91]), most clinical and
experimental evidence indicates that macrophages play a cen-
tral role in the GCW injury that leads to crescentic glomerulo-
nephritis, irrespective of whether the initial immune response is
predominantly humoral or cellular. This evidence is summa-
rized in Table 3.
Role of macrophages. Increased numbers of blood-borne
mononuclear cells, with features of monocytes/macrophages,
have been identified in the hypercellular glomerular tufts of
patients with proliferative glomerulonephritis [92—94] and in
animals with anti-GBM [76, 95—971 and serum sickness [98—1001
nephritis. A functional role for macrophages in GCW injury was
documented in two studies. Holdsworth et al showed that
specific depletion of macrophages prevented both the accumu-
lation of macrophages in glomeruli and the development of
proteinuria in a passive, autologous-phase model of anti-GBM
nephritis and in acute serum sickness in rabbits [101]. In
contrast to the heterologous phase of anti-GBM nephritis,
depletion of complement and neutrophils had no effect in these
models [101]. Schreiner and colleagues obtained similar results
in rats with accelerated autologous anti-GBM nephritis [75]. In
this model x-irradiation prevented glomerular hypercellularity,
glomerular influx of mononuclear cells, and proteinuria in the
autologous phase, but did not influence heterologous injury.
The factors that direct an influx of leukocytes appear to vary
according to the model employed. Thus, as I said, cell-mediated
immune mechanisms might be important in certain circum-
stances [72—74, 81, 82], whereas Fc-dependent [71, 102] or
complement-mediated [25, 70] immune adherence appears to
operate in others. It is also possible, but is as yet unproven in
glomerulonephritis, that immune adherence properties of acti-
vated endothelial cells [103], or the chemotactic effects of
locally produced platelet-activating factor (PAF) (104) and
leukotrienes [1051 could contribute to the glomerular localiza-
tion of macrophages.
The mechanisms by which macrophages damage the GCW
have not been defined but might be similar to those employed
by neutrophils, as shown in acute inflammatory models of
glomerular [62, 86] and pulmonary injury [59]. Neutrophil-
derived reactive oxygen species, especially hydrogen peroxide,
have been implicated in the pathogenesis of proteinuria in
experimental glomerulonephritis mediated by polymorphonu-
clear leukocytes [106, 107]. This effect appears to be at least
partly due to the halogenation of glomerular structures by
hypohalous acids generated from the reaction of hydrogen
peroxide with halide; this reaction is catalyzed by neutrophil-
derived myeloperoxidase that binds to the GCW by charge
interactions [108]. Macrophages are also an abundant source of
toxic oxygen metabolites [59]. Macrophages can also elaborate
neutral proteinases [69, 109] capable of digesting GBM matrix
components in vitro [110], and can produce a variety of potent
inflammatory mediators that have chemotactic and vasoactive
properties, such as PAF, thromboxane A2, and leukotrienes
[69, 104, 111]. Activated macrophages therefore are armed to
broach the integrity of the GCW; they allow leakage of plasma
proteins and clotting factors, including fibrinogen, into the
urinary space. Whatever the mechanisms, leukocyte-dependent
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GCW injury leads to disruption of the endothelium, breaks in
the continuity of the GBM, and the appearance of GBM
degradation products in the urine [31, 62].
Considering that intra- and extracapillary fibrin deposition is
prominent in crescentic glomerulonephritis [14—16, 112], it is
relevant that activated macrophages can produce tissue factor,
a phospholipoprotein cofactor that activates the extrinsic coag-
ulation cascade [113, 114], and prothrombinase, a prothrombin-
cleaving enzyme or enzyme complex [115]. Hancock and
Atkins used this property to identify tissue factor-positive
macrophages, together with fibrin, in the hypercellular glomer-
ular tufts and crescents of patients with proliferative GN [116].
I shalt discuss the functional importance of this observation in
a moment. Although it is not known what stimuli induce
macrophage-procoagulant activity (PCA) in glomerulonephritis,
in-vitro studies have shown that immunoglobulins, immune
complexes, endotoxin, and complement components can fulfill
this function [114, 115, 117, 118], especially in cooperation with
helper T cells [118].
The role of activated endothelial cells. Activated macro-
phages also produce interleukin 1 (IL-l) and tumor necrosis
factor (TNF, cachectin) [119, 120]. These cytokines stimulate
leukocyte migration and adhesion [119—121], and they activate
cultured human umbilical vein endothelial cells to express
tissue factor-like PCA, leukocyte-adhesion properties [103,
121—123], and a unique activation antigen [124]. However,
cultured human endothelial cells also can be activated by other,
macrophage-independent, stimuli such as endotoxin [103, 1221,
as well as by immune complexes and antibodies from patients
with SLE [1251. The expression of tissue factor and an endo-
thelial activation antigen was demonstrated recently in endo-
thelia of normal human glomeruli exposed in vitro to IL-i and
endotoxin [1261. Tissue factor also was detected in an endothe-
hal distribution (as well as in macrophages) in glomeruli of
patients with proliferative glomerulonephritis; this finding cor-
related with the presence of fibrin [126]. Certain endothelial
cells also manufacture PAF [104, 127], which might provide an
additional stimulus for leukocyte aggregation. Thus, in glomer-
ulonephritis, immune reactants might directly trigger endothe-
hal cells to express PCA and leukocyte-adhesion properties, or
this might occur in sequential fashion through macrophage-
derived IL-i or TNF. The proposed relationships are shown in
Figure 5.
The role of mesangial cells. "Endocapillary" proliferation,
that is, hypercellularity of the glomerular tuft, is due in part to
mesangial hypertrophy, and possibly hyperplasia, and occurs in
several forms of crescentic glomerulonephritis, especially in
those associated with mesangial immune deposits, such as SLE
and Henoch-Schonlein nephritis. In culture, rat mesangial cells
can be activated by several stimuli, including macrophage IL-l,
complement, endotoxin, and PAF [128—131]. These cells re-
spond by proliferating [1281 and/or by releasing potent inflam-
matory mediators that include prostaglandins [130—132], reac-
tive oxygen species [129], and mesangial IL-I [133]. These cells
also can produce PAF [134], as well as a neutral protease
capable of digesting GBM [135], and a growth factor that
resembles platelet-derived growth factor (PDGF) [1361. In
addition, mouse mesangial cells in culture produce a cytokine
that stimulates macrophages to secrete an IL-l—like factor
[137]. Such mediators have several potential effects. Aside from
the hemodynamic and tissue-damaging effects of prostanoids,
PAF, and toxic oxygen radicals produced by mesangial cells,
mesangial IL-l might stimulate endothelial cells to express PCA
and leukocyte-adhesion properties. Also, PDGF-like activity
could promote the proliferation of glomerular cells. Thus mech-
anisms exist by which immune and nonimmune stimuli such as
bacterial endotoxin, affecting primarily the mesangium, ulti-
mately could lead to hypercellularity, GCW injury, and local
activation of the extrinsic coagulation cascade.
The role of fibrin in crescent formation. I would now like to
discuss the long-recognized observation, so graphically illus-
trated by the case in point (Fig. 2), that fibrin deposition in
glomerular vessels and urinary space is common to all forms of
necrotizing and crescentic glomerulonephritis [14, 112]. As
illustrated in the accelerated autologous anti-GBM model, the
earliest indication of impending crescent formation is the ap-
pearance of fibrin in Bowman's space [15, 16]. Careful sequen-
tial analysis does reveal, however, that fibrin-related antigens
are first detectable within the glomerular tuft [15]. The impor-
tance of fibrin deposition in the genesis of a crescent was
convincingly shown by Naish, Thomson, and colleagues, who
found that defibrination with ancrod (a fibrinogen-splitting
enzyme from viper venom) effectively prevented the develop-
ment of crescents and abrogated the decline in renal function in
autologous anti-GBM and serum sickness nephritis [138, 139]
without inhibiting proteinuria [140] (Table 5). This finding
suggests that intraglomerular coagulation does not contribute to
GCW injury but is an important signal for the accumulation in
Bowman's space of cells that constitute a crescent. How fibrin
thrombi (or other products of coagulation or fibrinolysis) stim-
ulate the formation of a cellular crescent is still unknown, but
thrombin is known to be an effective chemotaxin for monocytes
[141].
Several counterbalancing procoagulant and anticoagulant
factors normally interact to maintain integrity of the vessel wall
while preventing formation of a fibrin thrombus on the endo-
thelial surface [142]. Endothelial cells synthesize various
procoagulants in vitro, including Factor VIII antigen (von
Willebrand factor), Factor V, thrombospondin, and tissue fac-
tor, and they can bind Factors IX/IXa and X. They also
synthesize anticoagulants such as prostacyclin, heparin-like
proteoglycans, and thrombomodulin, as well as fibrinolytic and
antifibrinolytic agents such as tissue plasminogen activator (PA)
and PA inhibitor. Although there is still much to be learned
about the state of individual procoagulant and anticoagulant
components in glomerulonephritis, new insights have been
gained into some of the stimuli that lead to glomerular fibrin
deposits.
The first appearance of fibrin in the glomerular tuft coincides
with the influx of tissue factor-positive macrophages in patients
with crescentic glomerulonephritis [1161 and with the occur-
rence of measurable PCA in the glomeruhi and urine of nephritic
rabbits [16]. The nature of the glomerular PCA is complex but,
at least initially, the PCA appears to include tissue factor [15,
16, 143]; this finding suggests that coagulation proceeds mainly
via the extrinsic cascade. Further evidence that macrophages
are important for the development of glomerular fibrin deposits
was provided by Holdsworth and Tipping in a passive-autol-
ogous model of anti-GEM nephritis in rabbits [144] (Table 6).
Glomerular fibrin deposition and PCA could be diminished by
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Table 5. Effect of defibrination on chronic immune-complex
(BSA-anti BSA) nephritis in rats'
Group
Fibrin
score
Crescent
score
Serum
creatinine
(mg/dl)
Urine
protein
(mg/mi)
Controls 1.06 1.38 4.30 12.4
Ancrodb 0.06 0.17 1.91 9.9
a Adapted from Ref. 139. Only mean values are shown for all animals
surviving until sacrifice on day 54.
b All values, except urine protein, are significantly lower in ancrod-
treated (defibrinated) rats.
monocyte depletion and partly restored by monocyte repletion
[144]. Cole and colleagues found increased expression of
prothrombinase in circulating monocytes of patients with se-
vere proliferative lupus nephritis but not in those of patients
with nonrenal lupus or end-stage nephritis [145]. Together,
these studies suggest that infiltrating macrophages, in addition
to damaging the GCW and allowing the passage of plasma
proteins into Bowman's space, initiate intravascular fibrin
deposition by activating the extrinsic coagulation pathway,
either directly by producing tissue factor or prothrombinase, or
indirectly by activating endothelial cells to express PCA (Fig.
5). The source of PCA responsible for activating extrinsic
coagulation pathway components that leak into the urinary
space is not yet known (Fig. 6). It could be derived from
macrophages that infiltrate Bowman's space but, if the chemo-
tactic stimulus for such migration originates from the fibrin cast,
an alternate source of PCA must exist in the urinary space prior
to macrophage influx. The source might be tissue factor,
released as phospholipid vesicles from injured glomerular cells.
Defective anticoagulant or fibrinolytic mechanisms also
might exist in certain forms of glomerulonephritis, and these
mechanisms might allow the formation of glomerular micro-
thrombi. Kant et al [146] and Glas-Greenwalt et al [147] have
described a subgroup of patients with severe lupus nephritis
who have glomerular microthrombi, depressed plasma levels of
vascular PCA, and increased levels of PCA inhibitor. Several
such patients had reversal of these abnormalities and stabiliza-
tion of renal function when treated with ancrod; the authors
attribute this outcome to improved fibrinolysis [147]. Failure of
some patients to improve correlated with elevated plasma levels
of a2-antiplasmin [146, 147]. In addition, inhibitors of fibrino-
lysis appear to exacerbate glomerular injury in experimental
crescentic glomerulonephritis [76, 1481.
Platelets, platelet antigens, and platelet-derived inflammatory
products all have been identified in proliferative and exudative
glomerulonephritis [149—151]. However, despite the gamut of
potential and established means by which platelets might pro-
voke or exacerbate the local inflammatory process and contrib-
ute to GCW injury [152, 153], no direct evidence has yet
confirmed that platelets participate in crescent formation.
Composition and morphogenesis of glomerular crescents
The composition of a glomerular crescent varies during its
metamorphosis. Beginning as a fibrin cast in Bowman's space,
it passes through a predominantly cellular phase to become a
fibrous scar (Fig. 6). As late as 1974, it was believed that
crescents were composed entirely of parietal epithelial cells
Table 6. Effect of monocyte-depletion and repletion on glomerular
fibrin deposition (GFD) and procoagulant activity (PCA) in
passive-autologous anti-GBM nephritis in rabbitsa
Mustine- Monocyte-
Untreated treated repleted
Glomerular macrophages
(macrophages/glom) 59.9 2.7 18.5
GFD (gfibrin/W glom) 5.4 1.6 3.5
Glomerular PCA (mU/JO3 glom) 171.0 56.0 100.0
a Adapted from Ref. 144. Only mean values are shown. Mustine
treatment depleted glomerular macrophages and significantly reduced
GFD and PCA compared With untreated controls. Monocyte repletion
partly restored these changes.
undergoing proliferation in response to fibrin in the urinary
space [14, 112]. Data summarized in Table 3 later suggested that
macrophages comprise the major cellular component of cres-
cents. Current evidence indicates, however, that early cres-
cents contain cells of mixed origin [93, 154—157] together with
fibrin, fibronectin and, in some cases, type IV collagen [158],
and that these cells are progressively replaced by interstitial-
type collagen.
In general, no more than 30% of the cells in a cellular crescent
are blood-derived mononuclear cells that have assumed the
properties of macrophages. This has been quantitatively shown
in human crescentic glomerulonephritis by histochemical stain-
ing for nonspecific esterase [156], by analysis of Y-body-
positive mononuclear cells in kidneys transplanted from fe-
males into male recipients [155], and by the use of monoclonal
antibodies that identify macrophage-phenotypic antigens [116,
157], In contrast, macrophages are prominent in the hypercel-
lular glomerular tufts in diseases in which there is marked
endocapillary proliferation, for example, lupus nephritis [159]
and essential mixed cryoglobulinemia [94]. These findings are in
accord with those of Cattell and Jamieson, who performed
experiments in which nephritic kidneys were transplanted into
recipient rabbits whose peripheral blood monocytes were pulse-
labeled with [3H]thymidine [154]. These authors found that
blood-derived monocytes contributed considerably to the early
hypercellularity of the glomerular tuft, but their studies showed
relatively few labeled monocytes in crescents [154]. In contrast,
in separate experiments they demonstrated substantial replica-
tion of intrinsic, presumably epithelial, cells [154]. These results
were supported by those of Magil, who examined human
crescentic glomeruli and found that up to 50% of cells stained
positively for cytokeratin, an intermediate filament found ex-
clusively in the cytoskeleton of epithelial cells [156]. In addi-
tion, the eventual appearance of interstitial collagen in fibrocel-
lular and fibrous crescents [158] suggests either that local cells
acquire the ability to secrete types I and/or III collagen, or that
fibroblasts also infiltrate the crescent through breaks in
Bowman's capsule [15, 24].
Factors responsible for stimulating the proliferation of pan-
etal epithelial cells and fibroblasts have not been identified, but
again, the macrophage is a prime candidate. Macrophages can
produce a variety of growth factors and cytokines that stimulate
fibroblast proliferation and collagen synthesis [160]. Although
numerically in the minority in crescents, macrophages might
exert a major local influence on crescent morphogenesis by
418 IVephrology Forum
Fig. 6. Proposed scheme of glomerular
crescent formation. Although all the events
depicted have been verified by clinical or
experimental observations (not necessarily
-j involving crescentic glomerulonephritis), fibrin
depletion is the only adequately tested
I manipulation shown to inhibit the formation of
- crescents.
providing the signals for cell replication and collagen synthesis
(Fig. 6). Additional factors must be considered, however,
because proliferation of intrinsic glomerular cells may occur
prior to the influx of monocytes in accelerated anti-GBM
nephritis in rats [161].
Conclusion
I have attempted to review much, although by no means all,
of the relevant data pertaining to the inflammatory response
that culminates in GCW injury, crescent formation, and the
clinical syndrome of RPGN. While one hestitates to take
experimental results painstakingly gathered by others, assem-
ble them according to one's own point of view, and present
them as a model, I believe that the schemes depicted in Figures
4 through 6 serve three main purposes. First, they summarize a
large body of clinical and experimental information, and allow
us to integrate clinical and experimental observations in cres-
centic glomerulonephritis and antibody-induced lung injury
with certain recent research advances in inflammation and
matrix chemistry. Second, they clarify the deficiencies in our
current knowledge. Finally, these schemes might help us in
identifying points along the inflammatory pathway that are
amenable to pharmacologic or immunologic manipulation.
Hopefully this information will lead us to devise more specific
ways than the use of high-dose corticosteroid or cytotoxic drugs
to prevent the activation of macrophages and other inflamma-
tory cells, and perhaps it even will yield the means of neutral-
izing the effects of soluble mediators released by already
activated cells.
Questions and answers
DR. JOHN T. HARR!NGTON (Chief, Department of Medicine,
Newton-Wellesley Hospital, Newton, Massachusetts): What is
your specific diagnosis in this patient and on what grounds did
you make it?
DR SALANT: Clinical information combined with a renal
biopsy showing necrotizing and crescentic glomerulonephritis
without immune deposits led me to believe that the patient had
early Wegener's granulomatosis. Should the patient have had
an open lung biopsy? The clinical spectrum suggested a
multisystem disease sufficiently for us to exclude idiopathic
deposit-free, crescentic glomerulonephritis and to begin ther-
apy with cyclophosphamide. Had her extrarenal symptoms not
resolved so quickly, a lung would have been biopsied. Consid-
ering the rapid resolution of this patient's hemoptysis and
pulmonary infiltrate, it seems unlikely that a lung biopsy on
presentation would have demonstrated granulomata. At best we
might have found necrotizing vasculitis, and I therefore wonder
at the diagnostic utility of lung biopsy in such "early" cases.
Let me emphasize, however, that open lung biopsy is still the
only definitive way to diagnose Wegener's granulomatosis and,
because the treatment is prolonged and hazardous, a biopsy
should be performed in all patients in whom the diagnosis is in
doubt or when adequate therapy fails to produce a prompt
improvement.
DR. JEROME P. KASSIRER (Associate Chairman, Department
of Medicine, Tufts University School of Medicine, Boston):
How would you have proceeded if you had been unable to carry
out a renal biopsy? How much did the biopsy results contribute
to this particular patient's management?
DR. SALANT: I would have obtained a serum anti-GBM
antibody as quickly as possible to exclude Goodpasture's
syndrome. If the antibody test had been positive, we would
have promptly treated the patient with plasmapheresis because
she fell into the "good prognostic" category of patients with
nonoliguric anti-GBM nephritis whose serum creatinine is less
than 6.5 mg/dl (Fig. 7). At the same time I would have measured
the ANA, serum complement, anti-streptolysin titers, cryoglob-
ulins, and hepatitis Bs because, if the anti-GBM were negative,
we would have had to rely on clinical and serologic features to
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exclude the systemic immune-complex diseases shown in Table
1. If these tests had been negative, we then could have decided,
according to the presence or absence of extrarenal symptoms,
whether the patient had vasculitis or idiopathic RPGN (im-
mune-complex or deposit-free) (Table 1, Fig. 7). The problem
with the "noninvasive" approach is the delay in obtaining the
resUlts of serologic studies. This is especially true of anti-GBM
assays. Few nephrologists have access to an indirect immuno-
fluorescence assay, and the shortest turnaround time we have
been able to find in a commercial laboratory that runs radioim-
munoassays for anti-GBM is 4 to 7 days. As I mentioned before,
the nature of the antigen substrate used in the radioimmunoas-
say is also critically important for achieving the reliability
reported by those who have developed these assays [5, 6, 40].
Because of the need for prompt action, and because the need
for, efficacy of, and type of treatment varies in each disease
(Fig. 7), 1 believe that renal biopsy, where possible, is the most
efficacious procedure in RPGN. In this particular patient,
immunofluorescent study of the renal biopsy allowed us to
distinguish among the three main causes of pulmonary-renal
syndrome (Table 2) and institute specific therapy within hours
of her admission.
DR. HARRINGTON: It seems to me that you are using the renal
biopsy primarily to exclude the possibility of anti-GBM disease.
Assuming that one had a rapid, sensitive, and specific serum
assay for anti-GBM antibodies, could you then not eliminate the
renal biopsy? Your treatment protocol for immune-negative and
immune complex-induced RPGN is identical.
DR. SALANT: Your question is most easily answered by
Figure 7. It is true that patients with idiopathic RPGN are
treated the same way whether or not they have immune
deposits; but most other diseases are treated differently. One
should also preface any remarks on the treatment of RPGN with
the disclaimer that most recommendations are based on largely
uncontrolled data [I, 6—9]. Further, we should moderate our
therapeutic aggressiveness according to the extent of renal
scarring shown on biopsy. Plasma exchange plus immunosup-
pressive drugs and steroids are recommended for nonoliguric
patients with anti-GBM nephritis who have well-preserved
renal function [6, 91, although some might argue that such
patients fare equally well with drug therapy alone [20]. Pulmo-
nary hemorrhage usually can be controlled with pulse steroids
[1, 29] or plasma exchange [6] irrespective of the level of renal
function, and nephrectomy is now rarely, if ever, indicated.
Unless the renal biopsy shows only cellular crescents without
fibrosis or scarring, dialysis-dependent patients with anti-GBM
nephritis who are oliguric are best treated conservatively with
dialysis followed by transplantation when anti-GBM titers are
no longer detectable by radioimmunoassay.
In patients with granular immune deposits, clinical symptoms
and serology usually help distinguish those with systemic forms
of immune-complex nephritis from those with primary renal
disease complicated by crescentic glomerulonephritis (Table 1).
The primary glomerulonephritides can be distinguished from
each other by the nature of the deposits on immunofluorescent
examination and electron microscopy. Eradication of the infec-
tion and supportive care are all that is needed in postinfectious
GN, whereas oral steroids, with or without immunosuppres-
sives [7] or initial pulse steroid therapy [II, are the mainstay of
treatment in lupus nephritis. Crescentic glomerulonephritis
complicating primary immune-complex glomerulonephritis gen-
erally responds poorly to treatment, but pulse therapy some-
times is effective. The results with plasma exchange are similar.
Pulse steroids and plasma exchange (plus immunosuppressive
drugs) are equally effective in idiopathic RPGN without im-
mune deposits [1, 9]. We favor pulse therapy because of its
familiarity, simplicity, and cost. In crescentic glomerulonephri-
tis without immune deposits, most patients with extrarenal
symptoms have a form of vasculitis such as Wegener's
granulomatosis or microscopic polyarteritis nodosa. These pa-
tients are best treated with cyclophosphamide and low-dose
steroids [8, 27].
Fig. 7. Algorithm for the management of rapidly progressive glomerulonephritis. GN, glomerulonephritis; GBM, glomerular basement
membrane; SLE, systemic lupus erythematosus.
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Da. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center Hospitals, Boston): We have
seen patients who have anti-GBM nephritis but no lung purpura
early in their presentation. Later in their course, when the
plasma level of anti-GBM antibody has decreased or even
become undetectable, lung purpura has become apparent. The
question is, what is the relationship between the level of
anti-GBM antibody and the development of lung purpura?
DR. SALANT: There is no simple relationship between circu-
lating levels of anti-GBM antibodies and the occurrence or
severity of pulmonary hemorrhage. The absence of such a
relationship suggests that the nature of the antibody and local
factors also are important determinants of lung injury [20, 31].
The phenomenon you describe has been recognized for some
time, but its cause is unknown 131]. In some cases the onset of
lung purpura has been attributed to superimposed infection or
fluid overload in patients with otherwise asymptomatic pulmo-
nary disease [31]. It is also worth noting that pulse steroids are
as effective as plasma exchange in controlling lung purpura
despite the more rapid disappearance of circulating anti-GBM
antibodies with plasmapheresis [20].
DR. DAVID B. BERNARD (Director of Clinical Nephrology,
Boston University Medical Center, Boston): It is intriguing that
certain therapies work better for some conditions than others,
as morphologically similar crescents can develop either in the
presence or absence of immune deposits. For example, does the
fact that cyclophosphamide is best for Wegener's granuloma-
tosis and steroids for some forms of idiopathic RPGN allow us
to define the most important component of the pathologic
process leading to crescent formation in these diseases? Also,
what is the current thinking about the place of anticoagulant or
thrombolytic therapy in these conditions?
DR. SALANT: In answer to your first question, treatment for
crescentic glomerulonephritis remains largely empiric. It is
tempting to oversimplify the issue and speculate that pulses of
steroids and cyclophosphamide are effective and rational ther-
apy in deposit-free idiopathic RPGN and vasculitis, respec-
tively, because they inhibit cell-mediated immunity. The truth
is, high-dose steroids and immunosuppressives are also effec-
tive antiinflammatory agents capable of influencing several
leukocyte functions, which may be equally or more important in
limiting tissue damage than in suppressing an already activated
immune response. Accelerated removal from the circulation of
pathogenetically important antibodies and inflammatory medi-
ators is probably the main reason why plasma exchange works
in some cases of anti-GBM nephritis. However, improvement
of mononuclear-phagocyte function and enhanced clearance of
circulating immune complexes [1621 is a clue that other, less
direct, effects of plasmapheresis also might be important.
Unfortunately, clinical experience in SLE nephritis indicates
that these effects are not of great therapeutic benefit to patients
with severe immune-complex nephritis [28].
You asked about anticoagulant therapy. Despite the impor-
tance of fibrin deposition in the formation of crescents,
anticoagulants, with or without oral steroids and immunosup-
pressives, have proved much less effective and more harmful
than simpler therapy with pulses of steroids and rapidly tapered
oral prednisone [1, 9], possibly because fibrin acts early in the
pathogenetic pathway. As I noted earlier, initial results in
patients with severe lupus nephritis and glomerular thrombi
who were treated with ancrod are encouraging [146, 147] and
merit more controlled studies.
DR. HARRINGTON: You mentioned the results of an
anticytoplasmic antibody titer early in this patient's course.
Can that test be used sequentially to determine the efficacy of
treatment in patients with Wegener's granulomatosis?
DR. SALANT: Yes. In one study that looked at this sequen-
tially, anticytoplasmic antibodies were present only during
active Wegener's granulomatosis and not during the inactive
phase [11]. The test also proved to be a more sensitive prospec-
tive marker of disease activity than did other acute-phase
reactants. I should stress, however, that the number of reports
and cases is still small.
DR. JOHN DONOHOE (Consultant Nephrologist, The National
Renal Unit, The Charitable Infirmary, Jarvis Street Hospital
and the Mater Misericordiae Hospital, Dublin, Ireland): What
is the presented patient's prognosis now that she has recovered
from the acute episode? Alternatively, what would you have
done had she gone on to end-stage renal failure as a result of
crescentic glomerulonephritis? Would you have considered her
a candidate for transplantation? Finally, is she likely to have a
recurrence of her disease at some later stage?
DR. SALANT: An update on 85 patients from the National
Institutes of Health (NIH) who were treated with chronic
low-dose cyclophosphamide reports a 93% overall remission
rate, with an average followup of 4 years [8]. Moreover, about
one-third of the NIH patients in remission were followed for an
average of 3 years after all treatment was discontinued [81.
Unfortunately, not all long-term studies of treated patients have
demonstrated the same degree of success. In series with a high
proportion of patients presenting with acute renal failure [541 or
advanced renal disease [21], mortality rates of 44% at 3 years
[54] and 50% after an average of 5 years [21] were recorded.
Relapse on withdrawal of cyclophosphamide occurs in up to
30% of cases, and it is therefore recommended that treatment
be continued for 12 to 15 months after induction of complete
remission [8]. An attempt should then be made to taper the drug
over about 6 months to limit the risk of long-term complications
such as hemorrhagic cystitis, leukopenia, leukemia, and lym-
phoma. Patients with Wegener's granulomatosis, or any other
form of crescentic glomerulonephritis, also are at risk for
long-term deterioration of renal function without the recurrence
of acute disease [21, 22].
Good results have been reported in several renal transplant
recipients maintained on conventional posttransplant therapy
(azathioprine and prednisone) [8, 22, 1631. Respiratory symp-
toms recurred in isolated cases but resolved when azathioprine
was replaced with cyclophosphamide [8, 164]; delay in changing
therapy was followed in one case by recurrence of Wegener's
nephritis and graft loss [165]. It is premature to formulate strict
guidelines for posttransplant therapy, but the following are
suggested. Patients should be in stable remission before under-
going transplantation and preferably should not be receiving
therapy; the choice of immunosuppressive drugs should be
guided by antirejection considerations; cyclophosphamide need
be included initially only if it was required before transplanta-
tion, but it should be introduced at the first evidence of
recurrent Wegener's granulomatosis. Experience with cyclo-
sporine A in transplant recipients with WG is even more
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limited. Dr. Bernard, would you like to describe our recent
encounter with such a patient?
DR. BERNARD: We recently had an interesting experience
with a patient with Wegener's granulomatosis who underwent
renal transplantation. She had been maintained for some years
on chronic hemodialysis, continuously received low-dose cy-
clophosphamide, and apparently was in remission. At the time
of transplantation, cyclophosphamide was discontinued, and
prednisone and cyclosporine were used as standard im-
munosuppressive therapy. About 3 weeks after successful
transplantation with normal graft function, a vigorous recur-
rence of pulmonary hemorrhage occurred, which fortunately
responded promptly to reinstitution of cyclophosphamide.
DR. MADIAS: Glomeruli of patients with Alport's syndrome
do not react with anti-glomerular basement membrane antibod-
ies. Does the specific defect in the glornerular basement mem-
brane of these patients, which recently was identified by
Kleppel et al 11661, correspond to the Goodpasture antigen?
DR. SALANT: Yes. The study you mention showed that
patients from certain cohorts with X-linked dominant familial
nephropathy (Alport's syndrome) lack one of the 3 NCI
glycopeptides (28 kD) that make up the globular domain of type
IV collagen in normal human GBM. The epitopes that make up
the Goodpasture antigen appear to reside on that peptide [38,
43], and its absence in Alport's syndrome accounts for the lack
of staining of basement membranes by Goodpasture antisera,
and for the risk of anti-GBM nephritis developing in normal
kidneys transplanted into recipients who have Alport's syn-
drome.
DR. GEETHA NARAYAN (Director, Tn-City Dialysis Center,
Medford, Massachusetts): How do you approach patients who
have idiopathic disease clinically, but in whom renal biopsy
reveals crescentic glomerulonephritis with immune deposits?
DR. SALANT: If a thorough clinical and serologic search for
systemic disease, including occult infection, is negative, the
patients should be treated the same way as those with idiopathic
RPGN without immune deposits (Fig. 7).
DR. HARRINGTON: Are there any experimental studies using
specific antibodies directed against some of the fundamental
components important in the genesis of crescents, such as
anti—IL-2 receptor antibodies?
DR. SALANT: I know of no studies that have directly exam-
ined the effect of such agents on crescent formation, but Kelly
and Strom recently inhibited the development of murine lupus
by treating young lupus-prone mice with anti—IL-2 receptor
antibodies [167]. This treatment probably worked more proxi-
mally in the immune response than the events shown in Figures
5 and 6, by inhibiting the proliferation of autoreactive lympho-
cytes.
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center Hospitals): In many patients,
periglomerular infiltrates of mononuclear cells are prominent.
Do these cells have a specific pathogenetic role? Do they have
prognostic significance?
DR. SALANT: Not much is known about the role and prog-
nostic significance of periglomerular mononuclear infiltrates. In
recent experimental observations by Eldredge and Wiggins, the
cells, as though responding to a chemotactic stimulus, appeared
to arise from interstitial venules and migrate towards glomeruli
at about the same time as the earliest crescents began to appear
[26]. The infiltrates are a mixture of histiocytes and lympho-
cytes that have the potential to disrupt Bowman's capsule,
stimulate proliferation of parietal epithelial cells, and induce
periglomerular fibrosis. It has yet to be determined whether or
not they do so.
DR. MADIAS: In view of the wide distribution of Goodpasture
antigen in various tissues, are there clinical examples of organ
involvement in addition to kidney and lung, as defined by
anti-glomerular basement membrane antibody deposition?
DR. SALANT: There are rare cases described of systemic
vasculitis in association with Goodpasture's syndrome, but the
role of anti-basement membrane antibodies in causing the
vasculitic lesions has not been well documented. The scarcity
of such lesions might be due to the relative impermeability of
extraglomerular endothelia.
DR. MADAI0: Can you speculate as to why the vasculitis in
certain patients with idiopathic RPGN appears to be confined to
the kidney?
DR. SALANT: I don't think the answer is known. It might, in
part, be a question of time and how hard one looks for
vasculitis. Neild and colleagues found that the glomerular
lesions, clinical course, and response to treatment did not differ
between patients with isolated, necrotizing glomerulitis and
those in whom a careful search revealed extraglomerular vas-
culitis [18]. The authors concluded that these patients might
comprise part of the spectrum of microscopic PAN. The same
might be true of IgA nephropathy—that could be regarded as
Henoch-Schonlein sans purpura.
DR. VINCENT J. CANZANELLO (Division of Nephrology, New
England Medical Center Hospitals): You indicated that differ-
ences in access of the anti-GBM antibody to basement mem-
brane antigen(s) might determine the presence or absence of
lung hemorrhage. Looking at the problem in a different way,
could this phenomenon result from differences in antibody
specificity? Is the anti-GBM antibody found in patients with
pulmonary and renal involvement identical to that in those who
do not have pulmonary hemorrhage?
DR. SALANT: Your point is well taken. Antibodies eluted
from the kidneys of patients with Goodpasture's syndrome may
be more reactive with lung tissue than are those eluted from
kidneys of patients with anti-GBM nephritis without lung hem-
orrhage [321. It is, therefore, quite possible that differences in
antibody activity or specificity, as well as the physical and
biochemical factors I discussed earlier, are important in deter-
mining susceptibility to lung purpura.
Reprint requests to Dr. D. Salant, Renal Section, University Hospi-
tal, 75 East Newton Street, Boston, Massachusetts 02118, USA
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